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Several drugs have been approved for treatment of multiple sclerosis (MS). Dimethyl 
fumarate (DMF) is utilized as an oral drug to treat this disease and is proven to be potent 
with less side effects than several other drugs. On the other hand, monomethyl fumarate 
(MMF), a related compound, has not been examined in greater details although it has 
the potential as a therapeutic drug for MS and other diseases. The mechanism of action 
of DMF or MMF is related to their ability to enhance the antioxidant pathways and to 
inhibit reactive oxygen species. However, other mechanisms have also been described, 
which include effects on monocytes, dendritic cells, T cells, and natural killer cells. It is 
also reported that DMF might be useful for treating psoriasis, asthma, aggressive breast 
cancers, hematopoeitic tumors, inflammatory bowel disease, intracerebral hemorrhage, 
osteoarthritis, chronic pancreatitis, and retinal ischemia. In this article, we will touch on 
some of these diseases with an emphasis on the effects of DMF and MMF on various 
immune cells.
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iNTRODUCTiON
Twenty years ago, there was no treatment for multiple sclerosis (MS). Today, there are wide varieties 
of immunomodulatory drugs, which have been licensed to treat MS patients. For relapsing-remitting 
MS (RRMS) patients, several drugs have been approved. During the 1990s, beta interferon and 
glatiramer acetate were the only drugs available. Other drugs, such as natalizumab, teriflunomide, 
and fingolimod, were later approved. These drugs modify the immune system to slow disease pro-
gression, decrease attacks, and reduce the development of new brain lesions.
Dimethyl fumarate (DMF) has been lately approved by the US Food and Drug Administration 
(FDA) as an oral drug for MS patients. This drug was first used to treat inflammatory skin diseases, 
such as psoriasis. The beneficial effects of this medication corroborated with regulating CD4+ Th1 
cell differentiation. In clinical trials, it showed positive benefits for MS patients by lowering risk of 
relapse and reducing the number of brain lesions (1–6).
The mechanism of action is not fully known. After oral intake, DMF is completely absorbed in the 
small intestine, and only small amounts are excreted in the feces and urine (7). DMF possesses a short 
half-life of ~12 min inside the body (8). After absorption, DMF is rapidly hydrolyzed by esterases 
to monomethyl fumarate (MMF) (9), which has a short half-life of 36 h. This molecule interacts 
FiGURe 1 | Chemical structures of DMF and MMF. Also shown is the structure of fumaric acid, the precursor molecule.
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with the immune cells in the blood circulation and crosses the 
blood–brain barrier (BBB) to the central nervous system (CNS) 
(10). Figure 1 shows the structures of DMF and MMF.
Dimethyl fumarate is an α, β-unsaturated carboxylic acid 
ester. It is demonstrated that DMF by activating nuclear factor 
erythroid 2-related factor (Nrf2), stimulated the production of 
glutathione (GSH), the cells most important scavenger of reac-
tive oxygen species (ROS) (11), hence, protecting against ROS-
induced cytotoxicity. Further studies demonstrate that DMF 
downregulated nuclear factor kappa B (NF-κB) in cells, inhibited 
the anti-apoptotic protein Bcl-2, and induced apoptosis. Cells 
challenged with oxidative stressors increase their antioxidant 
capacity as a response to increase ROS production and maintain 
homeostasis. Nrf2 acts as a key control of the redox gene tran-
scription; under oxidative stress, the Nrf2 signaling is activated 
to enhance the expression of a large number of antioxidants and 
enzymes that restore redox homeostasis. Nrf2 interacts with 
the cysteine-rich protein Kelch-like ECH-associated protein 1 
(Keap1) and acts as an adaptor protein for the Cul3-dependent 
E3 (Cul3) ubiquitin ligase complex. In normal conditions, Keap1 
promotes ubiquitination and repeatedly eliminates Nrf2 within 
a half-life of 13–21 min (12, 13). Keap1 possesses many cysteine 
residues in the amino acid terminal that act as sensors detecting 
changes in cellular redox state. During cellular stress, Keap1 is less 
effective at promoting Nrf2 degradation (12, 14).
Under normal conditions, Nrf2 is sequestered in the cytoplasm 
via binding to its inhibitory molecule Keap1. ROS/stress causes 
dissociation of Nrf2-Keap1 complex, leading to activation of Nrf2 
and its translocation into the nucleus. In the nucleus, Nrf2 het-
erodimerizes with other transcription factors, such as MAF, and 
consequently, binds the antioxidant responsive elements (ARE) 
in the target genes. Nrf2 promotes transcriptional activation of 
antioxidants and detoxifying enzymes. At the same time, phos-
phorylation of the repressor molecule IκB by ROS/stress causes 
activation of NF-κB, leading to activating gene transcription 
encoding inflammatory mediators. Studies have shown that Nrf2 
and NF-κB pathways have inhibitory influence on one another.
eFFeCTS OF DMF ON THe iNNATe 
iMMUNe SYSTeM
The main components of the innate immune system are epithelial 
barriers, leukocytes, dendritic cells (DCs), and natural killer (NK) 
cells. NK cells are large granular lymphocytes that spontaneously 
lyse target cells and are important for defending against viral 
infections as well as controlling tumor growth. NK cells have also 
immunoregulatory role by secretion of cytokines, chemokines, 
as well as cell-to-cell cross-talk (15). These cells express several 
activating and inhibitory receptors that detect target cells and 
control NK cell activity. In human, NK cells are divided by the 
expression of CD56 molecule into CD56dim and CD56bright subsets 
(15, 16).
The flow cytometric analysis of peripheral blood immune 
cells in 41 DMF-treated MS patients shows that these patients 
had significantly fewer circulating CD8+ T cells, CD4+ T cells, 
CD56dim NK cells, CD19+ B cells, and plasmacytoid DCs (17). 
Furthermore, the expression of CXCR3+ (a potential marker for 
Th1) and CCR6+ (a potential marker for Th17) was reduced, 
while the number of regulatory T cells (Treg) was unchanged. 
Interestingly, DMF did not affect circulating CD56bright NK cells, 
CD14+ monocytes, or myeloid DCs. However, DMF-treated 
patients had significantly fewer CD56dim NK cells when compared 
with healthy controls (17). A clinical study of 35 RRMS patients 
at baseline, 3 months, 6 months, and 12 months after initiation 
of DMF treatment shows that total leukocyte and lymphocyte 
counts diminished after 6  months, whereas after 12  months of 
DMF therapy total T cells counts decreased by 44%, CD8+ T cell 
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counts declined by 54.6%, and CD4+ T cell counts decreased by 
39% (18). CD19+ B cell counts were also reduced by 37.5%, and 
eosinophils counts were decreased by 54%, whereas the percent-
ages of neutrophils, monocytes, basophils, and NK cells were not 
significantly altered (18).
It has been previously demonstrated that MMF is a potent 
agonist of hydroxycarboxylic acid receptor 2 “(HCA2), a G 
protein coupled receptor also known as GPR109A” (19). It is 
reported that HCA2 mediates the therapeutic effects of DMF or 
MMF in experimental autoimmune encephalomyelitis (EAE) 
mouse model (20). Recently, we observed that MMF enhanced 
primary non-activated human CD56+ NK cell lysis of leukemic 
cell line K562 and B-cell lymphoma RAJI cells in  vitro (21). 
Furthermore, MMF upregulated NKp46 expression on the 
surface of CD56+ NK cells, an activity correlated with upregula-
tion of CD107a expression and the release of Granzyme B from 
CD56+ NK cells (21).
Moreover, MMF delayed EAE clinical score in SJL/J mice and 
prevented the disease progression in treated mice. These results 
are linked to enhanced NK cells lysis of DCs isolated from the 
same mice (22). To correlate these findings with human settings, 
we recently observed that human NK cells incubated with various 
concentrations of DMF or MMF robustly lysed immature DCs 
in  vitro (manuscript in preparation). These findings suggest 
that one mechanism of action for these “drugs” is plausibly due 
to activating NK cells to lyse DCs, and consequently, impeding 
antigen presentation to autoreactive T cells.
Dendritic cells represent key links between the innate and 
adaptive immune system (23). T cells and NK cells are stimulated 
through direct contact with activated DCs (24). DCs play a major 
role in regulating the immune response by releasing cytokines 
and expressing co-stimulatory molecules. They are capable 
of processing both exogenous and endogenous antigens and 
present them in the context of MHC class I or II molecules. It 
has been reported that DMF inhibited DCs maturation through 
a reduction in the release of the inflammatory cytokines IL-6 
and IL-12. Furthermore, DMF activated type II DCs, which have 
anti-inflammatory effects and suppressed type I DCs, which are 
inflammatory (25, 26). DMF induced type II DCs by regulating 
GSH depletion, followed by increased heme oxygenase-1 (HO-1) 
expression and suppressing STAT1 phosphorylation in DCs (26). 
This, combined with the reduction in the inflammatory cytokines 
by nuclear translocation of NF-κB, resulted in inhibiting CD1a, 
CD40, CD80, CD86, and HLA-DR expression (27). Consequently, 
the capacity of DCs to stimulate allogeneic Th1 and Th17 cells is 
reduced. It was also determined that increased production of the 
Th2 cytokines and increased expression of IL-10, instead of IL-12 
and IL-23 by DCs, enhanced the development of T regulatory 
(Treg) cells (28).
We reported that monocyte-derived DCs isolated from 
EAE mice treated with MMF did not increase the expression of 
CD80 molecule (22). Interestingly, E-cadherin expression was 
upregulated in EAE mice, and MMF reversed this upregula-
tion. Increased E-cadherin expression suggests a shifting of 
the immune system toward inflammatory Th1/Th17 response. 
These results support previous study showing that inflammatory 
E-cadherin+ bone marrow-derived DCs isolated from animals 
with colitis promoted Th17 response (29). The study also dem-
onstrates that E-cadherin+ DCs enhanced Th1 cell responses (29). 
Furthermore, E-cadherin+ DCs increased the number of IFN-γ+ 
CD4+ T cells and decreased the number of IL-4+ CD4+ T cells 
(30). MMF by decreasing E-cadherin expression on DCs may 
decrease inflammatory Th1/Th17 proliferation and may enhance 
the anti-inflammatory Th2 cells.
Although DMF but not MMF induced apoptosis in iDCs and 
moderately inhibited the ability of DCs to induce proliferation of 
allogeneic T cells, it is reported that MMF affected the polariza-
tion but not maturation of monocyte-derived DCs, resulting in 
downregulating Th1 lymphocyte responses (31). In vitro study 
for the effects of MMF on DCs differentiation shows that MMF 
inhibited monocyte-derived DCs differentiation in response to 
LPS, resulting in cells that are incapable of appropriately mature 
to DCs. In addition, MMF did not decrease the capacity of DCs to 
capture antigens, but MMF/DCs interaction resulted in produc-
ing low levels of IL-12, IL-10, and TNF-α, whereas IL-8 produc-
tion was not altered (32). Consequently, MMF/DCs interaction 
partially affected IFN-γ production by naive T cells, whereas the 
production of IL-4 and IL-10 was not influenced by MMF (32). 
Another study demonstrates that DMF inhibited DCs matura-
tion by reducing the production of the inflammatory cytokines 
IL-6 and IL-12 as well as the expression of MHC class II, CD80, 
and CD86 (27). Furthermore, immature DCs activated fewer 
T  cells characterized by low IFN-γ and IL-17 production (27). 
In contrast, de Jong et al. (33) demonstrate that MMF increased 
the production of IL-4 and IL-5 without altering the production 
of IL-2 and interferon-γ in stimulated peripheral blood mononu-
clear cells challenged with bacterial antigens.
TReATMeNT OF PSORiASiS AND OTHeR 
SKiN DiSeASeS wiTH DMF
Psoriasis is a type-1 cytokine-mediated chronic autoimmune skin 
disease aided by the infiltration of Th1/Th17 cells into the skin 
(34–36). DMF is utilized to treat psoriasis in European countries 
for more than 30 years. Fumaric acid was first used for treatment 
of psoriasis by the German chemist Walter Schweckendiek in 
1959. In 1994, DMF was licensed in Germany under the trade 
name Fumaderm for the treatment of psoriasis. DMF inhibited 
Janus kinas (JAK) signaling and interfered with intracellular 
proteins trafficking and consequently, inhibited the release of 
pro-inflammatory cytokines, such as IL-12, IL-23, and TNF, 
whereas the release of anti-inflammatory cytokines, such as 
IL-10, was increased. DMF also inhibited the production of IFN-
γ and enhanced the production of IL-10 in the culture of psoriatic 
keratinocytes (37).
Previous experimental and clinical studies were focused on 
the mechanism of action for DMF that could affect the immune 
system. The immunohistochemical studies of psoriatic plaques 
indicate that DMF has several anti-inflammatory effects via a 
number of pathways, leading to reduction in the levels of several 
inflammatory T cell subsets (38, 39) and decreased recruitment 
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of inflammatory cells (40). The ability of DMF or MMF to induce 
apoptosis of CD4+ and CD8+ T cells and in vitro switching the 
immune system toward a Th2 anti-inflammatory type response in 
psoriasis patients could be through impaired DCs maturation and 
induction of apoptosis. In addition, DMF inhibited the formation 
of new blood vessels, a process that is involved in the formation 
of psoriatic plaques (41).
Clinical studies demonstrate that DMF reduced CD4+ T cells 
and CD8+ T cells by inducing apoptotic cell death (42). In vivo 
studies indicate that DMF inhibited T cell mediated organ rejec-
tion in a rat model (43). A study of allergic contact dermatitis, 
a skin disorder in which an exaggerated T cell response occurs, 
shows that DMF suppressed allergen-induced T cell proliferation, 
corroborated with modulating cytokines/chemokines expression 
by reducing the levels of IFN-γ but not IL-5 and downregulating 
CXCR3 but not CCR4 expression (44).
TReATMeNT OF MULTiPLe SCLeROSiS 
PATieNTS wiTH DMF
Multiple sclerosis is a chronic inflammatory autoimmune 
disease of the CNS in which the insulating myelin sheaths of 
nerve cell axons in the brain and spinal cord are attacked by the 
immune system (45). The principal mechanism responsible for 
this disease is still incompletely understood. The consensus is 
that activated T cells attack oligodendrocytes, leading to destruc-
tion of myelin sheaths (demyelination). Furthermore, the pres-
ence of inflammatory T cells in the CNS triggers recruitment 
of more T cells, B cells, dendritic cells, microglia cells, and NK 
cells (46). Due to the progressive neurodegenerative nature of 
MS, therapeutic modalities that exhibit direct neuroprotective 
effects are needed. A phase 3 clinical trial study of 2667 RRMS 
patients demonstrates the efficacy and safety of DMF in MS (1). 
In vitro study indicates that DMF increased the frequency of the 
multipotent neurospheres resulting in the survival of mouse and 
rat neural stem progenitor cells (NPCs) following oxidative stress 
with hydrogen peroxide (H2O2) treatment (47). Using motor 
neuron survival assay, DMF significantly promoted survival 
of motor neurons under oxidative stress. Furthermore, DMF 
increased the expression of Nrf2 at both RNA and protein levels 
in the NPC cultures (47).
There is agreement that antioxidants reduce the risk of certain 
pathological conditions, such as neurodegenerative diseases. 
In vivo animal studies have shown that DMF or MMF inhibited 
the disease course in the EAE model (48). It is also demonstrated 
that MMF crossed the BBB, indicating it may have a direct 
cytoprotective function in the CNS (49). The detoxification 
capabilities of DMF or MMF reduced the production and release 
of inflammatory molecules, such as TNF-α, IL-1β, and IL-6 as 
well as nitric oxide from microglia and astrocytes activated with 
LPS in  vitro (50, 51). DMF or MMF increased the production 
of detoxification enzymes, such as nicotinamide adenine dinu-
cleotide phosphate quinone reductase 1 (NQO-1), HO-1, and 
cellular glutathione, abolishing NF-kB translocation into the 
nucleus (52). NQO-1 is also detected in the liver and in the CNS 
of DMF-treated animals. This results in decreased expression of 
NF-kB-dependent genes that regulate the expression of inflam-
matory cytokines, chemokines, and adhesion molecules, and 
consequently, reduced the damage to CNS cells. Reducing the 
expression of adhesion molecules in the BBB represents a critical 
step in the transmigration of immune cells into the CNS. DMF 
inhibited TNF-α-induced expression of intracellular adhesion 
molecule-1 (ICAM-1), E selection, and the vascular cell adhe-
sions molecule-1 (VCAM-1) in endothelial cells in vitro (53, 54). 
This is correlated with activating Nrf2 (55–58), which is released 
from the Keap-1complex via the activity of fumarates (see above). 
This may lead to reducing free radicals, preventing the synthesis 
of reactive nitrogen species, and thus protecting the CNS from 
degeneration and axonal loss (59, 60). These immunomodulatory 
activities of DMF or MMF, which constitute inhibiting cytokine 
production and nitric oxide synthesis, are important for the 
protection of oligodendrocytes against ROS-induced cytotoxicity 
and consequently, oligodendrocytes survival during an oxidative 
attack is augmented.
Multiple sclerosis animal models, such as EAE, are induced by 
immunization with different myelin antigens, such as proteolipid 
peptide (PLP139–151) in SJL/J mice, an animal model disease that 
may represent relapsing-remitting form of MS, or C57BL/6J mice 
immunized with MOG35–55, a model closely resembles chronic 
progressive MS. These models are characterized by inflammation, 
demyelination, and axonal lose. Treatment of EAE mice with 
DMF reduced macrophage-induced inflammation in the spinal 
cord (48). DMF suppressed Th1 and Th17 cell differentiation as 
well as expression of pro-inflammatory cytokines IFN-γ, TNF-α, 
and IL-17 (61). The drug also promoted Th2 cells that produce 
IL-4, IL-5, and IL-10 (33). In chronic MS, microglia cells are 
activated and released pro-inflammatory cytokines and stress-
associated molecules leading to neurodegeneration and alteration 
of synaptic transmission (62). Modulation of microglia activation 
toward an alternatively activated phenotype can modify the out-
come of some experimental models of neurological diseases. The 
study on EAE demonstrates that exposure to MMF switched the 
molecular and functional phenotype of activated microglia from 
pro-inflammatory type to neuroprotective effect (49). This switch 
in activity may occur through activation of HCAR2. MMF bind-
ing to HCAR2 triggered a pathway driven by the AMPK/Sirt axis 
resulting in inhibition of NF-κB and reducing pro-inflammatory 
cytokine production (49).
eFFeCTS OF DMF ON THe CeNTRAL 
NeRvOUS SYSTeM
A recent study reports that administration of DMF protected 
claudin-5 expression in the BBB along with reduced brain edema 
formation in C57BL/6 mice undergoing experimental ischemia 
reperfusion injury (63). Using the immortalized murine brain 
endothelial cell line bEND.3, a preservation of zonula occludens-1 
(ZO-1) and VE-cadherin localization in oxygen–glucose deprived 
cells in the presence of DMF was observed. Reduced transen-
dothelial migration of the human monocyte cell line THP-1 
toward CCL2 chemokine in the lower chamber of a transwell 
system after pretreatment of the bEND.3 cells with DMF was also 
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noted. Further observations demonstrate decreased ICAM-1, 
VCAM-1, and E-selectin mRNA expression in bEND.3 cells after 
treatment with DMF for 6 h (54).
In vitro human umbilical vein endothelium examination 
indicates that DMF or MMF modulated pro-inflammatory 
intracellular signaling and T-cell adhesiveness of human brain 
microvascular endothelial cells (64). Neither DMF nor MMF 
reduced the basal expression of ICAM-1 under inflammatory 
condition or blocked NF-κB in human brain microvascular 
endothelial cells compared to solvent control. Hence, it is sug-
gested that brain endothelial cells do not directly mediate a 
potential blocking effect of fumaric acid esters on the infiltration 
of inflammatory T cells into the CNS (64). It is also determined 
that DMF ameliorated inflammation, reduced BBB permeability 
and improved neurological outcomes by casein kinase 2 and Nrf2 
signaling pathways in experimental intracerebral hemorrhage 
(ICH) mouse model (65).
Evidence from clinical and animal studies suggests that 
inflammation and oxidative stress, which occur after hematoma 
formation, are involved in ICH-induced secondary brain injury 
and neurological dysfunction (66). VCAM-1 and ICAM-1 are 
adhesion molecules expressed in the endothelium important dur-
ing inflammation and after tissue injury. Both are increased upon 
activation of NF-κB-mediated TNF-α signaling pathway. TNF-α 
increases early onset endothelial adhesion by protein kinase 
C-dependent upregulation of ICAM-1 expression, which exacer-
bates ICH. Investigating the experimental autoimmune neuritis 
indicates that DMF treatment reduced the neurological deficits by 
ameliorating inflammatory cell infiltration and demyelination of 
sciatic nerves. In addition, DMF treatment decreased the level of 
pro-inflammatory M1 macrophages, while increasing the number 
of anti-inflammatory M2 macrophages in the spleens and sciatic 
nerves of EAN rats (67, 68). In RAW 264.7 macrophage cell line, 
a shift in macrophage polarization from M1 to M2 phenotype 
was demonstrated to be dependent on DMF application. In sciatic 
nerves, DMF treatment elevated the level of Nrf2 and its target 
HO-1, which may facilitate macrophage polarization toward M2 
type (68). In addition, by reducing NF-kB in astrocytes, DMF 
inhibited the degradation of IkBa and reduced the expression 
of nitric oxide synthase (69). Moreover, DMF improved the 
inflammatory milieu in the spleens of EAN rats, characterized by 
downregulating mRNA for IFN-γ, TNF-α, IL-6, and IL-17 and 
upregulating mRNA level for IL-4 and IL-10 (68).
eFFeCTS OF DMF ON TUMOR 
DeveLOPMeNT
It has been reported that fumarase is involved in DNA repair 
(70). By studying yeast cells, it is observed that cytosolic fumarase 
plays a role in detecting and repairing DNA damage, particularly 
double-stranded DNA breaks. According to this theory, if the 
cells lack the fumarase, they may need to repair damaged DNA 
and are most likely prone to develop tumors. Further study on 
the role of redox demonstrates that high levels of ROS are harm-
ful to normal cells and may lead to development of tumor by 
inducing DNA damage. Malignant transformation also increases 
cellular stress, leading to high ROS levels. On the other hand, 
Keap1-Nrf2 system protects cells from the effects of oxidants by 
regulating the expression of cytoprotective proteins (71). In vivo 
evidence indicates that Nrf2 has a protective role against tumor 
development in mouse models and in prostate cancer in humans 
(72). The mechanism by which Nrf2 is protective against tumor 
development has been attributed to the ability of Nrf2 to reduce 
the amount of ROS and DNA damages in cells.
It has also been demonstrated that DMF inhibited the prolif-
eration of A375 and M24met cell lines and reduced melanoma 
growth and metastasis in experimental melanoma mouse models 
(73). Furthermore, DMF arrested the cell cycle at the G2-M 
boundary and was pro-apoptotic, inhibiting tumor cell growth. 
On the other hand, MMF increased primary human CD56+ 
NK cell lysis of K562 and RAJI tumor cells, suggesting that this 
molecule may have in situ antitumor activity (21).
ROLe OF DMF iN GASTROiNTeSTiNAL 
ULCeRATiON
It has been demonstrated that stress can play a pathogenic role 
for gastrointestinal ulceration, by disrupting gastric mucosal 
defensive barrier (74). Activators of stress give rise to the release 
of corticotropin-releasing hormone (CRH). CRH acts on the 
pituitary gland and stimulates the secretion of ACTH, which 
promotes glucocorticoids release from the adrenal cortex (75). 
Glucocorticoids not only interfere with tissue repair, elevate levels 
of gastric acids, and pepsin but also reduce the secretion of gastric 
mucus and eventually impair gastric mucosal barrier resulting in 
peptic ulcer. Low daily oral doses of MMF may prevent the chronic 
foot-shock stress-induced gastric ulcers and may associate with dif-
ferential hormonal and oxidative processes (76). MMF suppressed 
the stress-induced elevation in adrenal gland corticosterone level 
and modulated the oxidative stress responses. Interestingly, DMF 
did not inhibit the effect of innate defense against microorgan-
ism. Treatment of monocytes and neutrophils with DMF after 
stimulation with Staphylococcus aureus, Escherichia coli, or the 
yeast Candida albicans in addition to zymosan particles or the 
tripeptide fMLP resulted in increased production of superoxide 
anion, which exerts anti-microbial effects (77).
eFFeCTS OF DMF ON COLLAGeN  
TYPe ii DeGRADATiON
In vivo study of collagen type II degradation suggests that DMF 
ameliorated the disease by inhibiting the expression of metallo-
proteinase (MMP)-1, MMP-3, and MMP-13 that are induced by 
TNF-α (78). DMF may attenuate MMPs expression by suppress-
ing JAK1 and JAK2/STAT3 pathways and by blocking TNF-α-
induced STAT3 phosphorylation and DNA-binding activity (79). 
In vivo mice study on renal fibrosis, where TGF-β plays a key role 
in the development of the disease, demonstrates that DMF treat-
ment may prevent renal fibrosis via Nrf2-mediated suppression 
of TGF-β signaling (80).
6Al-Jaderi and Maghazachi New Therapeutic Modalities for Cancer
Frontiers in Immunology | www.frontiersin.org July 2016 | Volume 7 | Article 278
CONCLUSiON AND FUTURe DiReCTiONS
Dimethyl fumarate was originally used for treatment of psoriasis. 
Its success in treating RRMS patients led for its approval as an 
oral drug to treat MS patients. One mechanism of action that our 
group pursued is that DMF might enhance natural killer cell lysis 
of dendritic cells, hence, impeding presenting encephalitogen to 
autoreactive T cells. Further investigations suggest that DMF 
may also be used in the oncology field due to its ability to sup-
press the growth of melanoma cells. On the other hand, it appears 
that related molecules, such as MMF, may have even more potent 
antitumor activity than DMF. Although the association among 
DMF and MMF is at present conjectural, it is documented that 
MMF has robust antitumor activity by activating natural killer 
cells to kill tumor cells. This new mechanism of action for MMF 
should provide imputes for investigating this molecule not 
only as a therapeutic tool for autoimmune diseases but also for 
cancer and immunodeficient diseases. Table 1 shows the current 
knowledge regarding the effects of DMF and MMF on various 
immune cells.
AUTHOR CONTRiBUTiONS
Both authors contributed to writing this review article.
TABLe 1 | immunoregulatory effects of DMF and/or MMF on various immune cells.
Cell type Molecule Cytokine/other molecules involved effect(s) Reference
T cells DMF/MMF ↓IFN-γ, ↓TNF-α, ↓IL-17, ↑IL-4, ↑IL-5, ↑IL-10, ↓CXCR3, 
↓CCR6
↓Bcl-2, ↑Apoptosis, ↓Th1, ↓Th17, ↑Th2, ↓CD4, ↓CD8, 
↑Treg
(17, 18, 27, 32, 
42, 44, 61)
B cells DMF ↑Nrf2→↑GSH→↓ROS, ↓NF-kB ↓Bcl-2, ↑Apoptosis, ↓CD19 B cells (17, 18)
Monocytes DMF ↑Nrf2, ↓NF-kB No effect on cell numbers, ↑Antioxidant response (18, 77)
DCs DMF/MMF ↓GSH→↑HO-1, ↓NF-kB, ↓IL-6, ↓IL-12, ↑IL-10, ↓TNF-α↓, 
E-cadherin
↑Apoptosis, ↓plasmacytoid DCs, ↓DC maturation, ↓type I 
DCs, ↑type II DCs
(17, 22, 25–27, 
31, 32)
NK cells DMF/MMF ↑NKp46, ↑CD107, ↑Granzyme B ↓CD56dim NK cells, No effect on CD56bright numbers, 
↑CD56bright NK cells lysis of tumor cells, ↑Lysis of DCS
(17, 18, 21, 22)
Macrophages DMF ↑Nrf2, ↓mRNA of IFN-γ, ↓mRNA of TNF-α, ↓mRNA of IL-6, 
↓mRNA of IL-17, ↑mRNA of IL-4, ↑mRNA of IL-10
↓M1 macrophages, ↑M2 macrophages (68)
Neutrophils DMF/MMF ↓HCA2 ↓Number of infiltrating neutrophils (20)
Keratinocytes DMF ↓IL-12, ↓IL-23, ↓TNF, ↓IFN-γ, ↑IL-10, ↓IL-6, ↓TGF-α ↓Proliferation of keratinocytes (37)
Endothelial cells DMF ↓TNF-α, ↓ICAM-1, ↓VCAM-1, ↓E-selection, ↑Nrf2 ↓BBB permeability→↓Immune cell migration (41, 54, 55, 65)
Microglia DMF/MMF ↓IL-1, ↓IL-6, ↓TNF-α, ↓NO, ↑Nrf2→↑GSH→↓ROS, 
↓NF-kB, ↑NQO-1, ↑HO-1, ↑HCAR2
↑Antioxidant response, switching activated microglia from 
pro-inflammatory to neuroprotective
(49, 50, 52)
Astrocytes DMF/MMF ↑Nrf2→↑GSH→↓ROS, ↓NF-kB, ↓IL-1, ↓IL-6, ↓TNF-α, ↓NO ↑Antioxidant response (50, 52, 58)
Neurons DMF ↑Nrf2→↑GSH→↓ROS ↓Apoptosis, ↑Neurons survival under oxidative stress (47, 58)
Tumor cells DMF Arrest the cell cycle at G2-M, ↓pro-apoptotic ↓Proliferation of melanoma cells, ↓Proliferation of tumor 
cells, ↑Apoptosis
(73)
↓, decreased; ↑, increased.
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